---
title: 'Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large
  B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium'
date: '2024-08-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39094076/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240803181300&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: In the standard-of-care setting, axi-cel exhibits outcomes
  consistent with those reported in clinical trials, with sustained, durable responses
  observed at the 5-year time point. However, late infections and the development
  of SMN are key survivorship issues that reduce long-term survival after CAR T-cell
  therapy, particularly in the ...'
disable_comments: true
---
CONCLUSION: In the standard-of-care setting, axi-cel exhibits outcomes consistent with those reported in clinical trials, with sustained, durable responses observed at the 5-year time point. However, late infections and the development of SMN are key survivorship issues that reduce long-term survival after CAR T-cell therapy, particularly in the ...